Destiny Pharma PLC 'leads the world' in new approach to preventing hospital infections

Digital Asset Direct by Destiny Pharma PLC

London, UK | November 21, 2022 09:19 AM Eastern Standard Time

Destiny Pharma PLC (AIM:DEST) chief scientific officer Bill Love spoke to Proactive as the company's XF-73 antibacterial drug begins a clinical study to prepare for a new drug application in the US. He explains the importance of developing this and Destiny's other lead drug amid the rise in antimicrobial resistance, how they work compared to antibiotics, how they can be used to reduce hospital-acquired infections and the size of the potential market.

Contact Details

Proactive

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com